Jiangbo Predicts $8-$12 Million First Year Sales of Hypertension Drug

Jiangbo Pharmaceuticals has received approval from the Shandong Food and Drug Administration to start selling a treatment for high blood pressure, Felodipine sustained release tablets. The company expects to sell $8 million to $12 million of the drug in the first 12 months at a 70% gross margin. More details... Stock Symbol: (NSDQ: JGBO)